Skip to main content

Advertisement

Table 6 PRO EQ-5D and QLQ-C30 subscale scores at baseline and safety follow-up

From: Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study

  KRASPRO analysis set PRO analysis set
WT KRAS(n = 76)a MT KRAS(n = 54)a Overall (n = 137)a
Baseline Safety follow-up Baseline Safety follow-up Baseline Safety follow-up
Mean (SD) EQ-5D subscale scores b
  Mobility 1.13 (0.34) 1.17 (0.38) 1.13 (0.34) 1.12 (0.42) 1.12 (0.33) 1.16 (0.41)
  Self care 1.05 (0.23) 1.14 (0.35) 1.13 (0.44) 1.15 (0.51) 1.08 (0.32) 1.15 (0.43)
  Usual activities 1.29 (0.56) 1.39 (0.60) 1.35 (0.59) 1.34 (0.65) 1.30 (0.56) 1.38 (0.62)
  Pain/discomfort 1.45 (0.58) 1.53 (0.56) 1.53 (0.58) 1.46 (0.56) 1.46 (0.57) 1.51 (0.56)
  Anxiety/depression 1.26 (0.50) 1.25 (0.44) 1.39 (0.49) 1.33 (0.48) 1.31 (0.49) 1.30 (0.46)
Mean (SD) QLQ-C30 functioning scores c
  Physical 71.7 (20.1) 71.3 (20.5)d 71.9 (19.6) 78.6 (10.5)d 72.5 (19.8) 74.3 (18.2)d
  Role 26.1 (33.4) 30.0 (33.3) 32.1 (35.0) 28.8 (29.8) 27.4 (33.7) 30.3 (31.2)
  Cognitive 10.2 (17.7) 13.3 (19.7) 13.6 (22.7) 14.1 (18.2) 11.0 (19.6) 14.4 (19.6)
  Emotional 24.3 (23.1) 22.1 (20.0) 26.5 (22.9) 14.9 (19.0) 24.6 (22.6) 19.8 (20.5)
  Social 25.8 (33.4) 25.7 (27.8) 23.5 (32.6) 16.7 (21.2) 23.6 (32.5) 22.4 (24.9)
Mean (SD) QLQ-C30 symptom scores e
  Fatigue 29.0 (27.8) 31.9 (28.3) 35.4 (31.6) 31.3 (22.6) 31.4 (28.8) 32.3 (26.0)
  Pain 19.1 (27.4) 22.9 (27.4) 25.3 (29.6) 19.3 (26.1) 21.2 (27.9) 21.6 (26.6)
  Nausea/vomiting 3.3 (10.6) 7.6 (14.2) 8.6 (19.1) 10.6 (19.9) 5.3 (14.6) 8.6 (16.8)
Mean (SD) QLQ-C30 single-item scores e
  Dyspnoea 17.1 (27.5) 21.0 (28.1) 23.5 (30.8) 21.2 (21.8) 19.2 (28.5) 21.3 (26.4)
  Insomnia 29.8 (35.8) 23.8 (28.7) 28.4 (32.0) 23.2 (27.0) 29.4 (34.2) 25.0 (28.9)
  Appetite loss 18.9 (31.0) 15.2 (30.6) 25.9 (35.3) 15.2 (27.8) 20.7 (32.4) 14.4 (28.4)
  Constipation 13.3 (23.2) 4.8 (14.3) 14.2 (25.6) 12.1 (23.3) 14.0 (23.8) 9.7 (22.0)
  Diarrhoea 20.7 (30.6) 12.4 (23.0) 19.1 (30.8) 22.2 (27.2) 19.5 (30.0) 18.1 (25.6)
  Financial impact 8.1 (20.5) 7.6 (18.2) 6.8 (17.6) 11.5 (26.2) 7.2 (18.8) 9.4 (22.0)
  1. aActual ‘n’ number may differ according to subscale item and time point (data from fewer patients were available at safety follow-up vs. baseline); bHigher scores indicate a better level of functioning of a greater degree of symptomology depending on subscale; cA higher score indicates a better level of functioning/health; cA higher score indicates a better level of functioning/health; dData not available at safety follow-up, data reported at week 48 instead; eA higher score indicates a greater degree of symptomology.